Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Neovacs to Present at Bio International Convention 2016 | ||
By: Nasdaq / GlobeNewswire - 30 May 2016 | Back to overview list |
|
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs to Present at Bio International Convention 2016 Paris and Boston, May 30 th , 2016 - Neovacs (Alternext Paris: ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Bio International Convention , one of the major international conventions focused on the biotechnology industry, being held June 6 to 9, 2016, in San Francisco, CA. The Convention brings together established and emerging leaders in the global biotechnology and pharmaceutical industry. In a presentation on Monday, June 6, at 2:30pm PDT (UTC-7 pm), Miguel Sieler, CEO of Neovacs will discuss the Company's proprietary Kinoid technology, providing updates about Neovacs' pipeline and strategic development programs for 2016/2017. He will also be accompanied by two members of the scientific management team: Dr Thérèse Croughs, Chief Medical officer, and Geraldine Vogel, Scientific Director of Neovacs. "We are pleased to participate in this event, which is an excellent opportunity to meet other major companies from our industry," commented Miguel Sieler, CEO of Neovacs. "This year, our participation will be more significant, as we obtained IND approval from the Food and Drug Administration in the United States for our Phase IIb study of IFNalpha Kinoid in the treatment of Lupus, which allows us to broaden our visibility and increase the interest in our technology platform." Meet Neovacs' team at booth #413, South & North Hall of the Moscone Center in San Francisco, California, USA About Neovacs Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha-Kinoid, an immunotherapy being developed for the indication of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
Investor Relations / Financial Communications Germany - MC Services
Press / U.S. Inquiries - The Ruth Group
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: NEOVACS via GlobeNewswire
HUG#2016361
|
||
|
||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |